Prevention of venous thromboembolism in surgical patients with breast cancer

British Journal of Surgery

Volumn 94, Issue 4, 2007, Pages 412-420

  Patiar, S ^a   Kirwan, C C ^a   McDowell, G ^a   Bundred, N J ^a   McCollum, C N ^a   Byrne, G J ^a  

^a WYTHENSHAWE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ENOXAPARIN; GESTAGEN; HEPARIN; HEPARIN CALCIUM; LEVONORGESTREL; LOW MOLECULAR WEIGHT HEPARIN; ORAL CONTRACEPTIVE AGENT;

BLEEDING; BREAST CANCER; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DATA BASE; DRUG EFFICACY; DRUG SAFETY; HEMATOMA; HUMAN; INTERMITTENT PNEUMATIC COMPRESSION DEVICE; LOW DRUG DOSE; MASTECTOMY; META ANALYSIS; PRIORITY JOURNAL; PROTECTIVE CLOTHING; RANDOMIZED CONTROLLED TRIAL; REVIEW; SURGICAL PATIENT; SYSTEMATIC REVIEW; VENOUS THROMBOEMBOLISM;

ADULT; AGED; ANTICOAGULANTS; BANDAGES; BREAST NEOPLASMS; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MASTECTOMY; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RISK FACTORS; THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 34247244710     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.5782     Document Type: Review

References (105)

1. Colditz GA, Tuden RL, Oster G. Rates of venous thrombosis after general surgery: combined results of randomised clinical trials. Lancet 1986; ii: 143-146.
2. Mismetti P, Laporte S, Darman JY, Buchmuller A, Decousus H. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg 2001; 88: 913-930.
3. Balas PE. Efficacy and safety of nadroparin (Fraxiparine) versus placebo in the prophylactic treatment of deep vein thrombosis in patients with high thrombo-embolic risk undergoing surgery. Thromb Res 1992; 65: (Suppl 1): S113 (Abstract).
4. Bergqvist D, Flordal PA, Friberg B, Frisell J, Hedberg M, Ljungstrom KG et al. Thromboprophylaxis with a low molecular weight heparin (tinzaparin) in emergency abdominal surgery. A double-blind multicenter trial. Vasa 1996; 25: 156-160.
5. Ho YH, Seow-Choen F, Leong A, Eu KW, Nyam D, Teoh MK. Randomized, controlled trial of low molecular weight heparin vs. no deep vein thrombosis prophylaxis for major colon and rectal surgery in Asian patients. Dis Colon Rectum 1999; 42: 196-202.
6. Le Gagneux F, Steg A, Le Guillou M. Subcutaneous enoxaparine (Lovenox) versus placebo for preventing deep vein thrombosis (DVT) after transurethral prostatectomy (TUP). Thromb Haemost 1987; 58: 116 (Abstract).
7. Marassi A, Balzano G, Mari G, D'Angela SV, Della Valle P, Di Carlo V et al. Prevention of postoperative deep vein thrombosis in cancer patients. A randomized trial with low molecular weight heparin (CY 216). Int Surg 1993; 78: 166-170.
8. Ockelford PA, Patterson J, Johns AS. A double-blind randomized placebo controlled trial of thromboprophylaxis in major elective general surgery using once daily injections of a low molecular weight heparin fragment (Fragmin). Thromb Haemost 1989; 62: 1046-1049.
9. Pezzuoli G, Neri Serneri GG, Settembrini P, Coggi G, Olivari N, Buzetti G et al. Prophylaxis of fatal pulmonary embolism in general surgery using low-molecular weight heparin CY 216: a multicentre, double-blind, randomized, controlled, clinical trial versus placebo (STEP). STEP-Study Group. Int Surg 1989; 74: 205-210.
10. Pezzuoli G, Neri Serneri GG, Settembrini PG, Coggi G, Olivari N, Negri G et al. Effectiveness and safety of the low-molecular-weight heparin CY 216 in the prevention of fatal pulmonary embolism and thromboembolic death in general surgery. A multicentre, double-blind, randomized, controlled clinical trial versus placebo (STEP). STEP Study Group. Haemostasis 1990; 20: (Suppl 1): 193-204.
11. Valle I, Sola G, Origone A. Controlled clinical study of the efficacy of a new low molecular weight heparin administered subcutaneously to prevent post-operative deep venous thrombosis. Curr Med Res Opin 1988; 11: 80-86.
12. Jorgensen LN, Wille-Jorgensen P, Hauch O. Prophylaxis of postoperative thromboembolism with low molecular weight heparins. Br J Surg 1993; 80: 689-704.
13. Collins R, Scrimgeour R, Yosuf S, Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med 1988; 318: 1162-1173.
14. Kakkar W. Efficacy and safety of Clivarin and other LMWHs in general surgery: a meta-analysis. Blood Coagul Fibrinolysis 1993; 4: (Suppl 1): S23-S27.
15. Koch A, Bouges S, Ziegler S, Dinkel H, Daures JP, Victor N. Low molecular weight heparin and unfractionated heparin in thrombosis prophylaxis after major surgical intervention: update of previous meta-analyses. Br J Surg 1997; 84: 750-759.
16. Koch A, Ziegler S, Breitschwerdt H, Victor N. Low molecular weight heparin and unfractionated heparin in thrombosis prophylaxis: meta-analysis based on original patient data. Thromb Res 2001; 102: 295-309.
17. Nurmohamed MT, Rosendaal FR, Buller HR, Dekker E, Hommes DW, Vandenbroucke JP et al. Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet 1992; 340: 152-156.
18. Palmer AJ, Schramm, W, Kirchhof B, Bergemann R. Low molecular weight heparin and unfractionated heparin for prevention of thrombo-embolism in general surgery: a meta-analysis of randomised clinical trials. Haemostasis 1997; 27: 65-74.
19. Thromboembolic Risk Factors (THRIFT) Consensus Group. Risk of and prophylaxis for venous thromboembolism in hospital patients. BMJ 1992; 305: 567-574.
20. Second Thromboembolic Risk Factors (THRIFT II) Consensus Group. Risk of and prophylaxis for venous thromboembolism in hospital patients. Phlebology 1998; 13: 87-97.
21. Shen VS, Pollak EW. Fatal pulmonary embolism in cancer patients: is heparin prophylaxis justified? South Med J 1980; 73: 841-843.
22. Svendsen E, Karwinski B. Prevalence of pulmonary embolism at necropsy in patients with cancer. J Clin Pathol 1989; 42: 805-809.
23. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ III. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 2000; 160: 809-815.
24. Clayton JK, Anderson JA, McNicol GP. Preoperative prediction of postoperative deep vein thrombosis. BMJ 1976; 2: 910-912.
25. Sue-Ling HM, Johnston D, McMahon MJ, Phillips PR, Davies JA. Pre-operative identification of patients at high risk of deep venous thrombosis after elective major abdominal surgery. Lancet 1986; i: 1173-1176.
26. Lieberman JS, Borrero J, Urdaneta AE, Wright IS. Thrombophlebitis and cancer. JAMA 1961; 177: 542-545.
27. Thodiyil PA, Kakkar AK. Variation in relative risk of venous thromboembolism in different cancers. Thromb Haemost 2002; 87: 1076-1077.
28. Donati MB. Cancer and thrombosis. Haemostasis 1994; 24: 128-131.
29. Clagett GP, Reisch JS. Prevention of venous thromboembolism in general surgical patients. Results of meta-analysis. Ann Surg 1988; 208: 227-240.
30. Clarke-Pearson DL, Jelovsek FR, Creasman WT. Thromboembolism complicating surgery for cervical and uterine malignancy: incidence, risk factors, and prophylaxis. Obstet Gynecol 1983; 61: 87-94.
31. Blarney SL, Lowe GD, Bertina RM, Kluft C, Sue-Ling LLM, Davies JA et al. Protein C antigen levels in major abdominal surgery: relationships to deep vein thrombosis, malignancy and treatment with stanozolol. Thromb Haemost 1985; 54: 622-625.
32. Falanga A, Ofosu FA, Cortelazzo S, Delaini F, Consonni R, Caccia R et al. Preliminary study to identify cancer patients at high risk of venous thrombosis following major surgery. Br J Haematol 1993; 85: 745-750.
33. Flordal PA, Bergguist D, Burmark US, Ljonstrom KG, Torngren S. Risk factors for major thromboembolism and bleeding tendency after elective general surgical operations. The Fragmin Multicentre Study Group. Eur J Surg 1996; 162: 783-789.
34. Kakkar W, Howe CT, Nicolaides AN, Renny JT, Clarke MB. Deep vein thrombosis of the leg. Is there a 'high risk group? Am J Surg 1970; 120: 527-530.
35. 125I-fibrinogen uptake test. Angiology 1980; 31: 606-613.
36. Walsh JJ, Bonnar J, Wright FW. A study of pulmonary embolism and deep leg vein thrombosis after major gynaecological surgery using labelled fibrinogen-phlebography and lung scanning. J Obstet Gynaecol Br Commonw 1974; 81: 311-316.
37. Adolf JBJ, Weidenbach A, Gmeinder F. Optimierung der postoperativen thromboseprophlaxe in der gynakologie. Geburtsh u Frauenheilk 1978; 38: 98-104.
38. Ballard RM, Bradley-Watson PJ, Johnstone FP, Kenney A, McCarthy TG. Low doses of subcutaneous heparin in the prevention of deep vein thrombosis after gynaecological surgery. J Obstet Gynaecol Br Commonw 1973; 80: 469-472.
39. Bonnar J, Walsh J. Prevention of thrombosis after pelvic surgery by British dextran 70. Lancet 1972; i: 614-616.
40. Turner GM, Cole SE, Brooks JH. The efficacy of graduated compression stockings in the prevention of deep vein thrombosis after major gynaecological surgery. Br J Obstet Gynaecol 1984; 91: 588-591.
41. Clarke-Pearson DL, Coleman RE, Synan IS, Hinshaw W, Creasman WT. Venous thromboembolism prophylaxis in gynecologic oncology: a prospective, controlled trial of low-dose heparin. Am J Obstet Gynecol 1983; 145: 606-613.
42. Clarke-Pearson DL, Creasman WT, Coleman RE, Synan IS, Hinshaw WM. Perioperative external pneumatic calf compression as thromboembolism prophylaxis in gynecologic oncology: report of a randomized controlled trial. Gynecol Oncol 1984; 18: 226-232.
43. Clarke-Pearson DL, Synan IS, Hinshaw WM, Coleman RE, Creasman WT. Prevention of postoperative venous thromboembolism by external pneumatic calf compression in patients with gynecologic malignancy. Obstet Gynecol 1984; 63: 92-98.
44. Clark-Pearson DL, DeLong E, Synan IS, Soper JT, Creasman WT, Coleman RE. A controlled trial of two low-dose heparin regimens for the prevention of postoperative deep vein thrombosis. Obstet Gynecol 1990; 75: 684-689.
45. Heilmann L, von Tempelhoff GH, Schneider D. Prevention of thrombosis prophylaxis in gynecologic malignancy. Clin Appl Thromb Haemost 1998; 4: 153-159.
46. Palfalvi L, Bosze P, Ungar L. Vascular injuries in the surgical management of gynaecological malignancies. Eur J Surg Oncol 1993; 19: 601-603.
47. Heidegger H, von Hugo R, Graeff H. Thromboembolism in gynecologic oncology. Eur J Gynaecol Oncol 1991; 12: 341-345.
48. Urlep-Salinovic V, Jelatancev B, Gorisek B. Prevention of postoperative thromboembolism in gynaecological malignancy. Eur J Gynaecol Oncol 1993; 14: 63-67.
49. Fisher B, Costantino J, Redmond C, Poisson R, Bowman D, Couture J et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 1989; 320: 479-484.
50. Saphner T, Tormey DC, Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol 1991; 9: 286-294.
51. Clahsen PC, van de Velde CJ, Julien JP, Floiras JL, Mignolet FY. Thromboembolic complications after perioperative chemotherapy in women with early breast cancer: a European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group study. J Clin Oncol 1994; 12: 1266-1271.
52. Wedgwood KR, Benson EA. Non-tumour morbidity and mortality after modified radical mastectomy. Ann R Coll Surg Engl 1992; 74: 314-317.
53. Kohro S, Yamakage M, Takahashi T, Ota K, Kondo M, Namiki A. Effects of intermittent pneumatic foot compression on blood coagulability and fibrinolysis assessed by a whole blood viscometer Sonoclot. J Anesth 2003; 17: 208-210.
54. Kumar S, Walker MA. The effects of intermittent pneumatic compression on the arterial and venous system of the lower limb: a review. J Tissue Viability 2002; 12: 58-66.
55. Chen AH, Frangos SG, Kilaru S, Sumpio BE. Intermittent pneumatic compression devices - physiological mechanisms of action. Eur J Vasc Endovasc Surg 2001; 21: 383-392.
56. Chouhan VD, Camerota A, Sun L, Harada R, Gaughan JP, Rao AK. Inhibition of tissue factor pathway during intermittent pneumatic compression: a possible mechanism for antithrombotic effect. Arterioscler Thromb Vasc Biol 1999; 19: 2812-2817.
57. Comerota AJ, Chouhan V, Harada RN, Sun L, Hosking J, Veermansunemi R et al. The fibrinolytic effects of intermittent pneumatic compression: mechanism of enhanced fibrinolysis. Ann Surg 1997; 226: 306-313.
58. Jacobs DG, Piotrowski JJ, Hoppensteadt DA, Salvator AE, Fareed J. Hemodynamic and fibrinolytic consequences of intermittent pneumatic compression: preliminary results. J Trauma 1996; 40: 710-717.
59. Borow M, Goldson H. Postoperative venous thrombosis. Evaluation of five methods of treatment. Am J Surg 1981; 141: 245-251.
60. Scurr JH, Coleridge-Smith PD, Hasty JH. Regimen for improved effectiveness of intermittent pneumatic compression in deep venous thrombosis prophylaxis. Surgery 1987; 102: 816-820.
61. Maxwell GL, Synan I, Dodge R, Carroll B, Clarke-Pearson DL. Pneumatic compression versus low molecular weight heparin in gynecologic oncology surgery: a randomized trial. Obstet Gynecol 2001; 98: 989-995.
62. Sigel B, Edelstein AL, Savitch L, Hasty JH, Felix WR JR. Type of compression for reducing venous stasis. A study of lower extremities during inactive recumbency. Arch Surg 1975; 110: 171-175.
63. Stewart GJ, Schaub RG, Niewiarowski S. Products of tissue injury. Their induction of venous endothelial damage and blood cell adhesion in the dog. Arch Pathol Lab Med 1980; 104: 409-413.
64. Jeffery PC, Nicolaides AN. Graduated compression stockings in the prevention of postoperative deep vein thrombosis. Br J Surg 1990; 77: 380-383.
65. Allan A, Williams JT, Bolton JP, LeQuesne LP. The use of graduated compression stockings in the prevention of postoperative deep vein thrombosis. Br J Surg 1983; 70: 172-174.
66. Amarigiri SV, Lees TA. Elastic compression stockings for prevention of deep vein thrombosis. Cochrane Database Syst Rev 2000; (3)CD001484.
67. Agu O, Hamilton G, Baker D. Graduated compression stockings in the prevention of venous thromboembolism. Br J Surg 1999; 86: 992-1004.
68. Fasting H, Andersen K, Kraemmer-Nielsen H, Husted SE, Koopmann HD, Simonsen O et al. Prevention of postoperative deep venous thrombosis. Low-dose heparin versus graded pressure stockings. Acta Chir Scand 1985; 151: 245-248.
69. Rasmussen A, Hansen PT, Lindholt J, Poulsen TD, Toftdahl DB, Gram J et al. Venous thrombosis after abdominal surgery. A comparison between subcutaneous heparin and antithrombotic stockings, or both. J Med 1988; 19: 193-201.
70. 99Tcm-plasmin. Acta Med Scand 1982; 211: 59-64.
71. ENOXACAN Study Group. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep venous thrombosis in elective cancer surgery: a double blind randomized multicentre trial with venographic assessment. Br J Surg 1997; 84: 1099-1103.
72. von Tempelhoff GF, Harenberg J, Niemann F, Hommel G, Kirkpatrick CJ, Heilmann L. Effect of low molecular weight heparin (Certoparin) versus unfractionated heparin on cancer survival following breast and pelvic cancer surgery: a prospective randomized double-blind trial. Int J Oncol 2000; 16: 815-824.
73. Lee RE, Ho KN, Karran SJ, Taylor I. Haemorrhagic effects of sodium heparin and calcium heparin prophylaxis in patients undergoing mastectomy. J R Coll Surg Edinb 1989; 34: 149-151.
74. Steele RJ, Richmond JD, Lee D, Chetty U, Davies GC. The effect of low-dose subcutaneous heparin on wound haemorrhage, a controlled study of mastectomy patients. Br J Clin Pract 1983; 37: 95-98.
75. Bakker XR, Roumen RM. Bleeding after excision of breast lumps. Eur J Surg 2002; 168: 401-403.
76. Nicolaides AN, Harbourne T, Russell RC. Subcutaneous heparin, plasma heparin levels and postoperative wound haematoma. Br J Surg 1984; 71: 62-64.
77. Hussien M, Lee S, Malyon A, Norrie J, Webster M. The impact of intraoperative hypotension on the development of wound haematoma after breast reduction. Br J Plast Surg 2001; 54: 517-522.
78. Anderson FA JR, Wheeler HB, Goldberg RJ, Hosmer DW, Patwardhan NA, Jovanovic B et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 1991; 151: 933-938.
79. Hull RD, Rakob CE, Gent M, McLoughlin D, Julian D, Smith FC et al. Effectiveness of intermittent pneumatic leg compression for preventing deep vein thrombosis after total hip replacement. JAMA 1990; 263: 2313-2317.
80. Nicolaides A, Irving D, Pretzell M, Dupont P, Lewis J, Desai S et al. The risk of deep-vein thrombosis in surgical patients. Br J Surg 1973; 60: 312.
81. Hansson PO, Sorbo J, Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. Arch Intern Med 2000; 160: 769-774.
82. Samama MM. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med 2000; 160: 3415-3420.
83. Nordstrom M, Lindblad B, Bergqvist D, Kjellstrom T. A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J Intern Med 1992; 232: 155-160.
84. Gillum RF. Pulmonary embolism and thrombophlebitis in the United States, 1970-1985. Am Heart J 1987; 114: 1262-1264.
85. Koster T, Rosendaal FR, de Ronde H, Briet F, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993; 342: 1503-1506.
86. Ridker PM, Miletich JP, Hennekens CH, Buring JE. Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening. JAMA 1997; 277: 1305-1307.
87. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PP, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995; 332: 912-917.
88. Simioni P, Prandoni P, Lensing AW, Scudeller A, Sandella C, Prins MH et al. The risk of recurrent venous thromboembolism in patients with an Arg506 → Gln mutation in the gene for factor V (factor V Leiden). N Engl J Med 1997; 336: 399-403.
89. Ridker PM, Miletich JP, Stampfer MJ, Goldhaber SZ, Lindpaintner K, Hennekens CH. Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation 1995; 92: 2800-2802.
90. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-3703.
91. Ridker PM, Hennekens CH, Miletich JP. G20210A mutation in prothrombin gene and risk of myocardial infarction, stroke, and venous thrombosis in a large cohort of US men. Circulation 1999; 99: 999-1004.
92. De Stefano V, Martinelli I, Mannucci PM, Paciaroni K, Rossi E, Chiusolo P et al. The risk of recurrent venous thromboembolism among heterozygous carriers of the G20210A prothrombin gene mutation. Br J Haematol 2001; 113: 630-635.
93. Martinelli I. Risk factors in venous thromboembolism. Thromb Haemost 2001; 86: 395-403.
94. Gerstman BB, Piper JM, Tomita DK, Ferguson WJ, Stadel BV, Lundin FE. Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am J Epidemiol 1991; 133: 32-37.
95. Farmer RD, Lawrenson RA, Thompson CR, Kennedy JG, Hambleton IR. Population-based study of risk of venous thromboembolism associated with various oral contraceptives. Lancet 1997; 349: 83-88.
96. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 1995; 346: 1582-1588.
97. Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995; 346: 1589-1593.
98. Lewis MA, Spitzer WO, Heinemann LA, MacRae KD, Bruppacher P, Thorogood M. Third generation oral contraceptives and risk of myocardial infarction: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women. BMJ 1996; 312: 88-90.
99. Lewis MA, Heinemann LA, MacRae KD, Bruppacher R, Spritzer WO. The increased risk of venous thromboembolism and the use of third generation progestagens: role of bias in observational research. The Transnational Research Group on Oral Contraceptives and the Health of Young Women. Contraception 1996; 54: 5-13.
100. British Medical Association and Royal Pharmaceutical Society of Great Britain. British National Formulary (51st edn). BMJ Publishing Group and RPSD Publishing: London, 2006.
101. Daly E, Vessey MP, Hawkins MM, Carson JL, Gough P, Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996; 348: 977-980.
102. Jick H, Derby LE, Myers MW, Vasilakis C, Newton KM. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 1996; 348: 981-983.
103. Grodstein F, Stampfer MJ, Goldhaber SZ, Manson JE, Colditz GA, Speizer FE et al. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 1996; 348: 983-987.
104. Grady D, Hulley SB, Furberg C. Venous thromboembolic events associated with hormone replacement therapy. JAMA 1997; 278: 477.
105. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-333.